| 1 |
Maron BJ, Mckenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy [J]. J Am Coll Cardiol, 2003, 42(9): 1687-1713.
|
| 2 |
Semsarian C, Ingles J, Maron MS, et al. New perspectives on the prevalence of hypertrophic cardiomyopathyl [J]. J Am Coll Cardio, 2015, 65(12): 1249-1254.
|
| 3 |
O'mahony C, Elliott PM. Prevention of sudden cardiac death in hypertrophic cardiomyopathy [J]. Heart, 2014, 100(3): 254-260.
URL
|
| 4 |
Elloitt PM, Polonieckij J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients [J]. J Am Coll Cardiol, 2000, 36(7): 2212-2218.
|
| 5 |
Task Force members, Elliott PM, Anastasakis A, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy [J]. Eur Heart J, 2014, 35(39): 2733-2779.
URL
|
| 6 |
宋雷, 邹玉宝, 汪道文, 等. 中国成人肥厚型心肌病诊断与治疗指南 [J]. 中华心血管病杂志, 2017, 45(12): 1015-1032.
|
| 7 |
Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy [J]. N Engl J Med, 2003, 348(4): 295-303.
|
| 8 |
Varma PK, Neema PK. Hypertrophic cardiomyopathy: part 1-introduction, pathology and pathophysiology [J]. Ann Card Anaesth, 2014, 17(2): 118-124.
|
| 9 |
Maron BJ, Doerer JJ, Haas TS, et al. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006 [J]. Circulation, 2009, 119(8): 1085-1092.
|
| 10 |
O'Mahony C, Jichi F, Pavlou M, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD) [J]. Eur Heart J, 2014, 35(30): 2010-2020.
URL
|
| 11 |
Elliott PM, Gimeno JR, Tome MT, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy [J]. Eur Heart J, 2006, 27(16): 1933-1941.
|
| 12 |
Green EM, Wakimoto H, Anderson RL, et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice [J]. Science, 2016, 351(6273): 617-621.
|
| 13 |
Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial [J]. Lancet, 2020, 396(10253): 759-769.
|
| 14 |
Schoendube FA, Klues HG, Reith S, et al. Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus [J]. Circulation, 1995, 92(9 Suppl): I122-I127.
|
| 15 |
Wang S, Cui H, Yu Q, et al. Excision of anomalous muscle bundles as an important addition to extended septal myectomy for treatment of left ventricular outflow tract obstruction [J]. J Thorac Cardiovasc Surg, 2016, 152(2): 461-468.
|
| 16 |
Minakata K, Dearani JA, Nishimura RA, et al. Extended septal myectomy for hypertrophic obstructive cardiomyopathy with anomalous mitral papillary muscles or chordae [J]. J Thorac Cardiovasc Surg, 2004, 127(2): 481-489.
|
| 17 |
Fang J, Wang R, Liu H, et al. Transapical septal myectomy in the beating heart via a minimally invasive approach: a feasibility study in swine [J]. Interact Cardiovasc Thorac Surg, 2020, 30(2): 303-311.
|
| 18 |
Lu M, Du H, Gao Z, et al. Predictors of outcome after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: an echocardiography and cardiovascular magnetic resonance imaging study [J]. Circ Cardiovasc Interv, 2016, 9(3): e002675.
|
| 19 |
Steggerda RC, Damman K, Balt JC, et al. Periprocedural complications and long-term outcome after alcohol septal ablation versus surgical myectomy in hypertrophic obstructive cardiomyopathy: a single-center experience [J]. JACC Cardiovasc Interv, 2014, 7(11): 1227-1234.
|
| 20 |
Rigopoulos AG, Panou F, Sakadakis E, et al. Cardiopulmonary exercise test parameters at three months after alcohol septal ablation in hypertrophic obstructive cardiomyopathy are associated with late clinical outcome [J]. Heart Lung Circ, 2020, 29(2): 202-210.
|
| 21 |
关怀敏, 解金红, 陈玉善, 等. 室间隔隧道化学消融术对肥厚梗阻性心肌病心肌的影响 [J]. 中国科技成果, 2018, 19(2): 38-40.
|
| 22 |
Vriesendorp PA, Van Mieghem NM, Vletter WB, et al. Microsphere embolisation as an alternative for alcohol in percutaneous transluminal septal myocardial ablation [J]. Neth Heart J, 2013, 21(5): 245-248.
URL
|
| 23 |
林国钦, 吴梅芳, 林俊敏, 等. 微球栓塞室间隔消融术治疗梗阻性肥厚型心肌病一例 [J]. 中华心血管病杂志, 2017, 45(7): 619-620.
|
| 24 |
Varma PK, Neema PK. Hypertrophic cardiomyopathy: part 1-introduction, pathology and pathophysiology [J]. Ann Card Anaesth, 2014, 17(2): 118-124.
|
| 25 |
Cooper RM, Shahzad A, Hasleton J, et al. Radiofrequency ablation of the interventricular septum to treat outflow tract gradients in hypertrophic obstructive cardiomyopathy: a novel use of CARTOSound® technology to guide ablation [J]. Europace, 2016, 18(1): 113-120.
|
| 26 |
Liu L, Liu B, Li J, et al. Percutaneous intramyocardial septal radiofrequency ablation of hypertrophic obstructive cardiomyopathy: a novel minimally invasive treatment for reduction of outflow tract obstruction [J]. EuroIntervention, 2018, 13(18): e2112-e2113.
|
| 27 |
Liu L, Li J, Zuo L, et al. Percutaneous intramyocardial septal radiofrequency ablation for hypertrophic obstructive cardiomyopathy [J]. J Am Coll Cardiol, 2018, 72(16): 1898-1909.
|